Showing 5391-5400 of 5659 results for "".
- Provectus Biopharmaceuticals Inc. Submits Application to FDA to Receive Breakthrough Therapy Designation for PV-10 for Treatment of Melanomahttps://practicaldermatology.com/news/20140325-provectus_biopharmaceuticals_inc_submits_application_to_fda_to_receive_breakthrough_therapy_designation_for_pv-10_for_treatment_of_melanoma/2459296/Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that it has applied to the FDA for Breakthrough Therapy Designation (BTD) for PV-10 for the treatment of melanoma. FDA guidelines state that
- Novan Announces Positive Phase 2 Results for Novel Acne Treatmenthttps://practicaldermatology.com/news/20140321-novan_announces_positive_phase_2_results_for_novel_acne_treatment/2459303/Novan Therapeutics announced today positive Phase 2 study results of its topical SB204 drug candidate for the treatment of acne vulgaris. Acne is a skin disease that affects more than fifty million people in the United States. The Phas
- FDA approves Impavido to treat tropical disease leishmaniasishttps://practicaldermatology.com/news/20140320-fda_approves_impavido_to_treat_tropical_disease_leishmaniasis/2459308/The US Food and Drug Administration approved Impavido (miltefosine) to treat a tropical disease called leishmaniasis. Leishmaniasis is a disease caused by Leishmania, a parasite which is transmitted to humans through sand fly bites. The disease occurs primarily in people who live in the tropics and
- Quinnova Pharmaceuticals Announces the Launch of Ecoza Foamhttps://practicaldermatology.com/news/20140319-quinnova_pharmaceuticals_announces_the_launch_of_ecoza_foam/2459310/Quinnova Pharmaceuticals LLC, an affiliate of Exeltis, launched its recently FDA-approved Ecoza (econazole nitrate) topical foam 1%. Ecoza Foma is indicated for the treatment of inter
- Antares Pharma Announces LEO Pharma's Launch of Otrexup (Methotrexate) Injection for Adults with Psoriasishttps://practicaldermatology.com/news/20140311-antares_pharma_announces_leo_pharmas_launch_of_otrexup_methotrexate_injection_for_adults_with_psoriasis/2459320/Antares Pharma, Inc. announced LEO Pharma's launch of Otrexup, the first FDA-approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. "We are very pleased that
- Allergies to Pre-Moistened Wipes on the Risehttps://practicaldermatology.com/news/20140303-allergies_to_pre-moistened_wipes_on_the_rise/2459326/A preservative in pre-moistened hand wipes may be linked to a rise of allergic reactions, according to dermatologist Matthew Zirwas, MD at the Ohio State University Wexner Center. He says manufacturers are increasing use of the preservative as they reduce their dependence on formaldehyde and para
- Registration Open for Dermatology Nurses' Associaion's 32nd Annual Conventionhttps://practicaldermatology.com/news/20140221-registration_open_for_dermatology_nurses_associaions_32nd_annual_convention/2459335/The Dermatology Nurses' Association's 32nd Annual Convention will be held Thursday, May 1, 2014 through Sunday, May 4, 2014 at the Walt Disney World Swan and Dolphin Hotel, in Orlando, FL. Online registration is
- Michelson Diagnostics Launches Enhanced Software for VivoSight OCT Scannerhttps://practicaldermatology.com/news/20140219-michelson_diagnostics_launches_enhanced_software_for_vivosight_oct_scanner/2459339/Michelson Diagnostics recently launched its upgraded VivoSight Optical Coherence Tomography (OCT) scanner with a new software technology that provides additional f
- Kerecis Receives US Patent for Fish-Skin-Based Tissue Regeneration Technologyhttps://practicaldermatology.com/news/20140219-kerecis_receives_us_patent_for_fish-skin-based_tissue_regeneration_technology/2459340/A US patent was awarded to Kerecis Limited for the use of fish skin in medical applications. The Kerecis material consists of sheets of intact, decellulariz
- DEKA Medical Receives FDA Clearance for the Synchro REPLA:Yhttps://practicaldermatology.com/news/20140213-deka_medical_receives_fda_clearance_for_the_synchro_replay/2459343/The FDA cleared DEKA Medical, Inc.'s Synchro REPLA:Y, an aesthetic workstation dedicated, but not limited, to high speed stable long-term, or permanent hair reduction, treatment of PFB, treatment of benign pigmented lesions, treatment of wrinkles and